Suggested Dosing of Select Beta-lactam Agents for the Treatment of Antimicrobial-Resistant Gram-Negative Infections in Children.

This article focuses on providing pediatric-specific dosing recommendations for β-lactam antibiotics used to treat antimicrobial-resistant (AMR) gram-negative infections, serving as a companion to the Infectious Diseases Society of America (IDSA) adult AMR treatment guidance. A panel of pediatric infectious diseases specialists reviewed pharmacokinetic/pharmacodynamic and clinical data to suggest dosing regimens for newer β-lactam agents—including cefiderocol, ceftazidime-avibactam (with or without aztreonam), ceftolozane-tazobactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam, sulbactam-durlobactam, and ampicillin-sulbactam—across neonates, infants, children, and adolescents with normal renal and hepatic function. The document discusses the rationale for dosing, efficacy targets, central nervous system penetration considerations, and highlights gaps in pediatric data, emphasizing the importance of optimizing antibiotic dosing to improve outcomes in children with AMR infections.